Arrange the drug in decreasing order of antiplatelet potency a. Clopidogrel b. Prasugrel c. Aspirin d. Abciximab
## **Core Concept**
The question tests the understanding of antiplatelet drugs and their potency. Antiplatelet drugs work by inhibiting platelet aggregation, which is a crucial step in the formation of thrombi. They act on different targets, including cyclooxygenase (COX) enzymes, P2Y12 receptors, and glycoprotein IIb/IIIa receptors.
## **Why the Correct Answer is Right**
The correct order of decreasing antiplatelet potency is: Abciximab > Prasugrel > Clopidogrel > Aspirin.
- **Abciximab** is a monoclonal antibody that inhibits the glycoprotein IIb/IIIa receptor, a key receptor involved in platelet aggregation. Its inhibition provides immediate and potent antiplatelet effects.
- **Prasugrel** and **Clopidogrel** are thienopyridines that irreversibly inhibit the P2Y12 receptor. Prasugrel is more potent and has a faster onset of action compared to clopidogrel because it is more efficiently converted to its active form.
- **Aspirin** acts by irreversibly inhibiting COX-1, which is involved in the production of thromboxane A2, a potent stimulator of platelet aggregation. Its effect is less potent compared to the direct inhibition of platelet receptors or aggregation pathways.
## **Why Each Wrong Option is Incorrect**
- **Option A:** This option does not correctly represent the decreasing order of potency.
- **Option B:** This option suggests a wrong order, placing aspirin as more potent than prasugrel and abciximab, which is incorrect.
- **Option C:** This option also suggests an incorrect order, not accurately reflecting the potency of these drugs.
## **Clinical Pearl / High-Yield Fact**
A key point to remember is that the choice of antiplatelet drug depends on the clinical scenario, including the risk of thrombotic events and bleeding. For example, abciximab is often used in acute coronary syndromes and during percutaneous coronary interventions (PCIs) for its potent antiplatelet effect.
## **Correct Answer:** .